Loading company…
Minervax develops vaccines against Group B Streptococcus, with its lead candidate AlpN GBS moving toward Phase 3.
Founded in 2010 and based in Copenhagen, Denmark, Minervax ApS develops vaccines for Group B Streptococcus (GBS) infections, mainly for pregnant women and older adults. Its lead candidate, AlpN GBS, is advancing toward Phase 3 clinical trials. CEO Per Fischer guides the company. It has completed 16 deals and raised EUR 54.00 mn in its latest round, led by Adjuvant Capital and Novo Holdings, with nearly EUR 200 mn raised overall. Kinled Holding made a recent investment. The company is at Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in